AGENUS INC (AGEN) Fundamental Analysis & Valuation

NASDAQ:AGEN • US00847G8042

2.92 USD
-0.28 (-8.75%)
At close: Mar 5, 2026
2.9995 USD
+0.08 (+2.72%)
After Hours: 3/5/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AGEN. AGEN was compared to 520 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. AGEN is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. AGEN Profitability Analysis

1.1 Basic Checks

  • AGEN had negative earnings in the past year.
  • In the past year AGEN has reported a negative cash flow from operations.
  • AGEN had negative earnings in each of the past 5 years.
  • In the past 5 years AGEN reported 4 times negative operating cash flow.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -15.13%, AGEN is in the better half of the industry, outperforming 79.23% of the companies in the same industry.
Industry RankSector Rank
ROA -15.13%
ROE N/A
ROIC N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • With an excellent Gross Margin value of 98.93%, AGEN belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AGEN has remained more or less at the same level.
  • AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. AGEN Health Analysis

2.1 Basic Checks

  • AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • AGEN has more shares outstanding than it did 1 year ago.
  • AGEN has more shares outstanding than it did 5 years ago.
  • AGEN has a worse debt/assets ratio than last year.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -14.08, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
  • AGEN has a Altman-Z score of -14.08. This is in the lower half of the industry: AGEN underperforms 79.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.08
ROIC/WACCN/A
WACC5.66%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

2.3 Liquidity

  • AGEN has a Current Ratio of 0.47. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.47, AGEN is not doing good in the industry: 90.58% of the companies in the same industry are doing better.
  • AGEN has a Quick Ratio of 0.47. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.47, AGEN is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.47
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. AGEN Growth Analysis

3.1 Past

  • AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.05%, which is quite impressive.
  • The Revenue for AGEN has decreased by -33.41% in the past year. This is quite bad
  • Measured over the past years, AGEN shows a decrease in Revenue. The Revenue has been decreasing by -7.17% on average per year.
EPS 1Y (TTM)81.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
Revenue 1Y (TTM)-33.41%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%20.4%

3.2 Future

  • AGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.41% yearly.
  • Based on estimates for the next years, AGEN will show a quite strong growth in Revenue. The Revenue will grow by 16.37% on average per year.
EPS Next Y91.44%
EPS Next 2Y46.39%
EPS Next 3Y22.51%
EPS Next 5Y15.41%
Revenue Next Year0.26%
Revenue Next 2Y29.88%
Revenue Next 3Y4.37%
Revenue Next 5Y16.37%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

4

4. AGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 1.91, the valuation of AGEN can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, AGEN is valued cheaper than 99.42% of the companies in the same industry.
  • AGEN is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.82, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.91
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as AGEN's earnings are expected to grow with 22.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.39%
EPS Next 3Y22.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AGEN Dividend Analysis

5.1 Amount

  • No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AGEN Fundamentals: All Metrics, Ratios and Statistics

AGENUS INC

NASDAQ:AGEN (3/5/2026, 8:00:01 PM)

After market: 2.9995 +0.08 (+2.72%)

2.92

-0.28 (-8.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-09
Inst Owners29.66%
Inst Owner Change13.04%
Ins Owners1.7%
Ins Owner Change0.38%
Market Cap105.53M
Revenue(TTM)106.83M
Net Income(TTM)-35.38M
Analysts80
Price Target12.58 (330.82%)
Short Float %12.58%
Short Ratio6.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-88.19%
Min EPS beat(2)-172.44%
Max EPS beat(2)-3.94%
EPS beat(4)2
Avg EPS beat(4)-29.02%
Min EPS beat(4)-172.44%
Max EPS beat(4)38.98%
EPS beat(8)3
Avg EPS beat(8)-44.03%
EPS beat(12)5
Avg EPS beat(12)-28.61%
EPS beat(16)8
Avg EPS beat(16)-21.22%
Revenue beat(2)0
Avg Revenue beat(2)-48.06%
Min Revenue beat(2)-49.33%
Max Revenue beat(2)-46.8%
Revenue beat(4)0
Avg Revenue beat(4)-29.94%
Min Revenue beat(4)-49.33%
Max Revenue beat(4)-10.55%
Revenue beat(8)1
Avg Revenue beat(8)-20.83%
Revenue beat(12)3
Avg Revenue beat(12)-9.34%
Revenue beat(16)6
Avg Revenue beat(16)-1.64%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1460.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-175.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.91
P/S 0.99
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)1.53
Fwd EY52.28%
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.47
OCFYN/A
SpS2.96
BVpS-7.59
TBVpS-8.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.93%
FCFM N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.62%
Cap/Sales 0.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.47
Altman-Z -14.08
F-Score2
WACC5.66%
ROIC/WACCN/A
Cap/Depr(3y)280.5%
Cap/Depr(5y)277.58%
Cap/Sales(3y)20.35%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
EPS Next Y91.44%
EPS Next 2Y46.39%
EPS Next 3Y22.51%
EPS Next 5Y15.41%
Revenue 1Y (TTM)-33.41%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%20.4%
Revenue Next Year0.26%
Revenue Next 2Y29.88%
Revenue Next 3Y4.37%
Revenue Next 5Y16.37%
EBIT growth 1Y37.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.17%
EBIT Next 3Y-10.15%
EBIT Next 5Y-10.98%
FCF growth 1Y65.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.4%
OCF growth 3YN/A
OCF growth 5YN/A

AGENUS INC / AGEN FAQ

Can you provide the ChartMill fundamental rating for AGENUS INC?

ChartMill assigns a fundamental rating of 2 / 10 to AGEN.


Can you provide the valuation status for AGENUS INC?

ChartMill assigns a valuation rating of 4 / 10 to AGENUS INC (AGEN). This can be considered as Fairly Valued.


What is the profitability of AGEN stock?

AGENUS INC (AGEN) has a profitability rating of 2 / 10.


Can you provide the financial health for AGEN stock?

The financial health rating of AGENUS INC (AGEN) is 0 / 10.


Can you provide the dividend sustainability for AGEN stock?

The dividend rating of AGENUS INC (AGEN) is 0 / 10 and the dividend payout ratio is 0%.